KRAS and non-small cell lung carcinoma: In recent years, a substantial advance occurred through the identification and development of covalent allosteric inhibitors especially targeting KRAS G12C (1–4), a mutation that comprises 41% of KRAS non–small cell lung cancer (NSCLC) (5).